INT4145

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.77
First Reported 1976
Last Reported 2011
Negated 2
Speculated 3
Reported most in Body
Documents 124
Total Number 128
Disease Relevance 44.98
Pain Relevance 13.04

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (FSHR) plasma membrane (FSHR) signal transducer activity (FSHR)
Anatomy Link Frequency
follicle 37
plasma 13
urine 5
ovary 5
thyroid 3
FSHR (Homo sapiens)
Pain Link Frequency Relevance Heat
narcan 48 99.98 Very High Very High Very High
Endogenous opioid 10 99.76 Very High Very High Very High
agonist 583 99.54 Very High Very High Very High
methadone 15 98.68 Very High Very High Very High
Fibrositis 172 98.66 Very High Very High Very High
antagonist 460 97.96 Very High Very High Very High
Central nervous system 20 97.96 Very High Very High Very High
opiate 14 97.92 Very High Very High Very High
headache 47 97.40 Very High Very High Very High
Bioavailability 43 96.04 Very High Very High Very High
Disease Link Frequency Relevance Heat
Endometriosis (extended) 308 100.00 Very High Very High Very High
Reprotox - General 3 627 99.78 Very High Very High Very High
Polycystic Ovary Syndrome 326 99.60 Very High Very High Very High
Hypogonadotropic Hypogonadism 397 99.44 Very High Very High Very High
Ovarian Hyperstimulation Syndrome 255 99.36 Very High Very High Very High
Reprotox - General 2 148 99.12 Very High Very High Very High
Cancer 166 99.02 Very High Very High Very High
Stress 116 99.00 Very High Very High Very High
Fibromyalgia 169 98.66 Very High Very High Very High
Pituitary Cancer 37 98.56 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This modulated temporal profile is likely to produce more sustained and less fluctuating plasma FSH levels during rhFSH administration.
Gene_expression (produce) of FSH in plasma
1) Confidence 0.77 Published 2009 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2764710 Disease Relevance 0 Pain Relevance 0
Levels of follicle stimulating hormone (FSH), estradiol and inhibin were measured annually.
Gene_expression (Levels) of FSH in follicle
2) Confidence 0.77 Published 1999 Journal Climacteric Section Body Doc Link 11910659 Disease Relevance 0.08 Pain Relevance 0
Levels of follicle stimulating hormone (FSH), estradiol and inhibin were measured annually.
Gene_expression (Levels) of follicle stimulating hormone in follicle
3) Confidence 0.77 Published 1999 Journal Climacteric Section Body Doc Link 11910659 Disease Relevance 0.08 Pain Relevance 0
Recombinant DNA engineering technology allows for the production of human FSH in Chinese hamster ovary cells [4].
Gene_expression (production) of FSH in ovary
4) Confidence 0.75 Published 2003 Journal Reprod Biol Endocrinol Section Body Doc Link PMC270000 Disease Relevance 0.62 Pain Relevance 0
Advances in molecular biology techniques made it possible to produce recombinant FSH, which is secreted from genetically engineered Chinese hamster ovary cells [4].
Gene_expression (produce) of FSH in ovary
5) Confidence 0.75 Published 2003 Journal Reprod Biol Endocrinol Section Body Doc Link PMC270000 Disease Relevance 0.16 Pain Relevance 0.06
One cycle of treatment with gonadotropins requires 20 to 30 L of urine from postmenopausal women.4 The increased demand for gonadotropins and the advances in molecular technology lead to the production of recombinant FSH.
Gene_expression (production) of FSH in urine
6) Confidence 0.71 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2971716 Disease Relevance 0.25 Pain Relevance 0
In the mid 1990s highly purified urinary FSH became available containing less than 0.1% LH and virtually no urinary proteins, allowing subcutaneous administration.2 The production of highly purified FSH was enabled by the development and application of production techniques based on immuno affinity chromatography with monoclonal antibodies.
Gene_expression (production) of FSH
7) Confidence 0.71 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2971716 Disease Relevance 0.33 Pain Relevance 0
By transfecting a Chinese hamster ovary cell line with FSH genes recombinant FSH could be stably produced and was introduced in clinical practice in 1992.9 Recombinant FSH is homogenous and free of contamination by proteins.
Gene_expression (produced) of FSH in ovary
8) Confidence 0.71 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2971716 Disease Relevance 0.17 Pain Relevance 0
In fact at 48 hours after rhFSH injections, 10 out of 12 cases in abdominal injection group surpassed the FSH threshold while only 3 out of 12 cases in vaginal injection group had serum FSH concentration over the FSH threshold of 7.8 IU/L (Figure 4).
Gene_expression (threshold) of FSH
9) Confidence 0.67 Published 2009 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2764710 Disease Relevance 0 Pain Relevance 0
There are few shortcomings in the original design of this trial including (1) the small numbers of the subject enrolled which might result in less significant power in the statistical analysis; and (2) the endogenous FSH was not fully suppressed which made it difficult to provide a reliable pharmacokinetic analysis especially in the elimination half-life.
Neg (not) Gene_expression (suppressed) of FSH
10) Confidence 0.67 Published 2009 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2764710 Disease Relevance 0 Pain Relevance 0.03
Besides the rapid absorption as described above, another characteristic of the vaginal injection mode observed in this study is the extended and prolonged smoother temporal profile of plasma FSH levels.
Gene_expression (levels) of FSH in plasma
11) Confidence 0.67 Published 2009 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2764710 Disease Relevance 0 Pain Relevance 0
As the present study employed a single dose injection of rhFSH, the serum FSH level elaborated may not sustain enough to override the window of threshold for proper follicular growth and there were only transiently elevated levels of E2 detected in both groups.
Gene_expression (level) of FSH
12) Confidence 0.67 Published 2009 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2764710 Disease Relevance 0 Pain Relevance 0
Though the endogenous FSH was not fully suppressed in the present study, the estimation of elimination half-life of 46 hours in abdominal SC injection of the present study is similar to that of 37 hours in SC/IM [16,17], and 44 hours in IM [21] single 300 IU rhFSH injections.
Neg (not) Gene_expression (suppressed) of FSH
13) Confidence 0.67 Published 2009 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2764710 Disease Relevance 0 Pain Relevance 0.09
Subcutaneous injection of FSH can cause some side reactions, depending on variables such as medicines, needle size and injected volume.
Gene_expression (injection) of FSH
14) Confidence 0.67 Published 2009 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2764710 Disease Relevance 0.09 Pain Relevance 0.04
Compared with urinary FSH products, the benefits of follitropin alpha lie in its reliable supply, consistency of production, lack of contaminant urinary proteins and ease of self-administration.
Gene_expression (products) of FSH
15) Confidence 0.66 Published 1998 Journal BioDrugs Section Abstract Doc Link 18020563 Disease Relevance 0.61 Pain Relevance 0.07
Tolerability has not differed between follitropin alpha and other FSH products.
Gene_expression (products) of FSH
16) Confidence 0.66 Published 1998 Journal BioDrugs Section Abstract Doc Link 18020563 Disease Relevance 0.71 Pain Relevance 0.10
The incidence of general events (e.g. headache, nausea, ovarian cyst), local irritations at injection site and ovarian hyperstimulation syndrome resembled those for comparator FSH products.
Gene_expression (products) of FSH associated with ovarian hyperstimulation syndrome, reprotox - general 3, vomiting and headache
17) Confidence 0.66 Published 1998 Journal BioDrugs Section Abstract Doc Link 18020563 Disease Relevance 0.78 Pain Relevance 0.10
The clinical implications of differing isoform profiles for FSH products are unclear and there are no convincing data to suggest marked superiority of either human-derived or animal-derived FSH formulations for ovarian stimulation in terms of efficacy or safety [7-14].
Gene_expression (products) of FSH
18) Confidence 0.65 Published 2003 Journal Reprod Biol Endocrinol Section Body Doc Link PMC270000 Disease Relevance 0.13 Pain Relevance 0
Secondary efficacy variables included the percentage of cycles with oocyte retrieval; duration of gonadotropin therapy; total FSH dose; peak serum E2 levels; embryo transfer and implantation rates; chemical pregnancies (positive serum ?
Gene_expression (dose) of FSH in embryo
19) Confidence 0.65 Published 2003 Journal Reprod Biol Endocrinol Section Body Doc Link PMC270000 Disease Relevance 0 Pain Relevance 0
During the first week, both follicle-stimulating hormone (FSH) and LH were undetectable.
Gene_expression (undetectable) of FSH in follicle
20) Confidence 0.63 Published 1989 Journal Fertil. Steril. Section Abstract Doc Link 2494080 Disease Relevance 0 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox